A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients who met all of the following criteria were included:
Had a confirmed diagnosis of melanoma recorded during the identification period, and
Had at least 6 months of enrollment before the index date A, where index date A was defined as the first date of a confirmed diagnosis of melanoma recorded during the identification period, and
Were at least 18 years old at the time of initiation of the first line of treatment (LoT).
The Adjuvant Dab+Tram Cohort included all patients who met all of the following criteria:
Had a dabrafenib prescription claim and a trametinib prescription claim recorded after or at the index date A, and
Had at least 6 months of follow-up after the index date B, where index B was defined as the first date of a prescription recorded at or after index date A, and
Had the first dabrafenib or trametinib prescription claim recorded within 12 weeks of an excision surgery, and
Did not have a confirmed metastasis diagnosis recorded within 1 month before, at, or within 12 weeks after the index date A.
The Non-adjuvant Dab+Tram Cohort included all patients that met all of the following criteria:
Had a dabrafenib prescription claim and a trametinib prescription claim recorded after or at the index date A, and
Had at least 6 months of follow-up after the index date B, and
Not included in the Adjuvant Dab+Tram Cohort.
The Cohort Enco+Bini included all patients that met all of the following criteria:
Had an encorafenib prescription claim and a binimetinib prescription claim recorded after or at the index date A, and
Had at least 6 months of follow-up after the index date B.
The Overall Cohort included all patients that met all of the following criteria:
Included in either the Adjuvant Dab+Tram Cohort, the Non-adjuvant Dab+Tram Cohort, or the Enco+Bini Cohort. A patient could be considered in multiple cohorts and was considered once only in analysis of the Overall Cohort.
You may not be if
Had a prescription claim with a melanoma treatment recorded within 6 months before the index date A, or
Had a confirmed diagnosis of a non-small cell lung cancer recorded any time before the index date A for the Adjuvant Dab+Tram Cohort and the Non-adjuvant Dab+Tram Cohort, or
Had a confirmed diagnosis of a colorectal cancer recorded any time before the index date A for the Enco+Bini Cohort.
Clareo Health | A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan
